Prucalopride, a medication approved to treat constipation, improved cognitive function in people with a history of depression, according to a small clinical trial. Participants who took the drug for approximately one week showed measurable gains on tests measuring memory, attention, and thinking speed compared to those receiving placebo.
The drug works by targeting a serotonin receptor present in both the gastrointestinal tract and the brain. This dual-site mechanism explains its original constipation indication while opening potential therapeutic applications for post-depression cognitive symptoms. Researchers observed no significant adverse effects during the trial period.
Depression frequently produces persistent cognitive deficits even after mood symptoms resolve. Patients describe this residual impairment as "brain fog," a state marked by difficulty concentrating, slower processing, and memory problems. Current treatments focus primarily on mood stabilization rather than cognitive restoration, leaving this aspect of recovery largely unaddressed.
The trial size remains small, limiting definitive conclusions about efficacy and safety in broader populations. Researchers have not yet identified the specific mechanisms by which prucalopride enhances cognition or determined optimal dosing schedules for this potential new application. Long-term effects remain unstudied.
If validated in larger trials, prucalopride could offer a repurposed therapeutic option with existing safety data and manufacturing infrastructure. The finding exemplifies how drugs developed for one condition sometimes address unrelated health problems when their mechanisms interact with disease biology in unexpected ways.
The researchers did not specify which institution conducted the work or publish details about sample size, participant demographics, or statistical measures of improvement. These details remain necessary to assess the strength and generalizability of the findings. Additional trials with larger cohorts and extended follow-up periods would clarify whether prucalopride represents a genuine therapeutic advance for post-depression cognitive dysfunction or a preliminary observation requiring substantial further investigation.